Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib First-Line Followed by Chemotherapy in Advanced NSCLC
NCT00217698Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 2003
- Primary completion
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Swiss Group for Clinical Cancer Research. Started Nov 2003; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00217698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00217698.